Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ: BMRN )

70.54 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 25
Open 70.54
Bid (Size) 67.84 (1)
Ask (Size) 72.22 (1)
Prev. Close 70.54
Today's Range 70.54 - 70.54
52wk Range 60.63 - 94.85
Shares Outstanding 183,352,255
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
1 Healthcare Stock to Target This Week and 2 to Turn Down
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
+6.09%
+6.09%
1 Month
+11.09%
+11.09%
3 Month
+6.93%
+6.93%
6 Month
-16.80%
-16.80%
1 Year
-17.19%
-17.19%

More News

Read More
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Demystifying Biomarin Pharmaceutical: Insights From 8 Analyst Reviews
Via Benzinga
Earnings Scheduled For February 19, 2025
Via Benzinga
NASDAQ:BMRN, a growth stock which is not overvalued.
Via Chartmill
Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect
Via StockStory
What To Expect From United Therapeutics’s (UTHR) Q4 Earnings
Via StockStory
What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings
Via StockStory
Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today
Via The Motley Fool
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today
Via StockStory
Why Is BioMarin Stock Trading Higher On Thursday?
Via Benzinga
BioMarin: EPS Surges Past Expectations
Via The Motley Fool
BioMarin Pharmaceutical (NASDAQ:BMRN) Reports Bullish Q4, Stock Soars
Via StockStory
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings
Via StockStory
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
Via Chartmill
NASDAQ:BMRN is an undervalued gem with solid fundamentals.
Via Chartmill
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Via Benzinga
NASDAQ:BMRN is showing decent growth, but is still valued reasonably.
Via Chartmill
Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators
Via Benzinga
Topics ETFs
10 Magnificent Stocks That Can Make You Richer in 2025
Via The Motley Fool
NASDAQ:BMRN stands out as a stock that provides good value for the fundamentals it showcases.
Via Chartmill
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.